Last reviewed · How we verify
Zanubrutinib Oral Product
At a glance
| Generic name | Zanubrutinib Oral Product |
|---|---|
| Also known as | Zanubrutinib |
| Sponsor | UMC Utrecht |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL (PHASE2)
- BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma (PHASE2)
- Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma (PHASE2)
- Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma (PHASE2)
- Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ (PHASE2)
- Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM (PHASE2)
- Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL (PHASE2)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zanubrutinib Oral Product CI brief — competitive landscape report
- Zanubrutinib Oral Product updates RSS · CI watch RSS
- UMC Utrecht portfolio CI